Sunday, 15 November 2026European Markets

DSM KON And 3 Other Stocks Have Very High Payout Ratio

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Loading stream...

(vianews) - acomo (acomo.as), totens sparebank (totg.ol), axa (cs.pa) are the highest payout ratio stocks on this list.

here's the data we've collected of stocks with a high payout ratio as yet. the payout ratio in itself isn't a promise of a future good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.

when researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.

1. acomo (acomo.as)

56.76% payout ratio

acomo n.v., together with its subsidiaries, engages in sourcing, trading, processing, packaging, and distributing conventional and organic food ingredients and solutions for the food and beverage industry worldwide. it operates through five segments: spices and nuts, edible seeds, organic ingredients, tea, and food solutions. the spices and nuts segment provides tropical products, including pepper, nutmeg, desiccated coconut, shelled and unshelled nuts, dried fruits, dehydrated vegetables, herbs, rice crackers, and snack products. its edible seeds segment trades, processes, and distributes edible seeds, such as poppy, sesame, pumpkin, and flax, as well as sunflower seeds comprising in-kernel and shelled for the snack and retail industries; birdseeds for wildlife; and edible seeds to bakery, spice, and confectionery industries. the organic ingredients segment provides a range of organic food products and ingredients in various categories, including cocoa, coffee, fruit and vegetables, edible seeds, nuts and dried fruits, oils, and premium juice products. its tea segment trades, processes, and distributes through warehouses and blending facilities; and monitors and analyzes market development, and shares insight to customers to meet traditional consumer preferences, which include novel appetites for specialty tea. the food solutions segment produces and supplies culinary and functional ingredients, plant-based solutions, wet and dry blends, and spice mixes to food companies; and provides product development, manufacturing, packaging, distribution, and inventory management services. the company was formerly known as amsterdam commodities n.v. and changed its name to acomo n.v. in june 2022. acomo n.v. was founded in 1908 and is based in rotterdam, the netherlands.

earnings per share

as for profitability, acomo has a trailing twelve months eps of €1.85.

pe ratio

acomo has a trailing twelve months price to earnings ratio of 11.84. meaning, the purchaser of the share is investing €11.84 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.08%.

yearly top and bottom value

acomo's stock is valued at €21.90 at 22:10 est, way under its 52-week high of €24.50 and way higher than its 52-week low of €18.06.

volume

today's last reported volume for acomo is 2095 which is 89.05% below its average volume of 19135.

dividend yield

according to morningstar, inc., the next dividend payment is on apr 25, 2023, the estimated forward annual dividend rate is 1.25 and the estimated forward annual dividend yield is 5.58%.

sales growth

acomo's sales growth for the current quarter is 0.8%.

more news about acomo.

2. totens sparebank (totg.ol)

52.38% payout ratio

totens sparebank provides various banking and financial products and services in norway. the company offers savings and pension products; business and construction loans; leasing; overdrafts and bank guarantees; liability, business, data attack, property damage, craftsman, health, homeowners, collective, personnel, travel, occupational injury, agriculture, and vehicle insurance; and business and credit cards. it also provides online and mobile banking services; payment solutions; asset management; and real estate services. totens sparebank was founded in 1854 and is headquartered in lena, norway.

earnings per share

as for profitability, totens sparebank has a trailing twelve months eps of kr20.54.

pe ratio

totens sparebank has a trailing twelve months price to earnings ratio of 9.69. meaning, the purchaser of the share is investing kr9.69 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.47%.

moving average

totens sparebank's worth is below its 50-day moving average of kr218.04 and below its 200-day moving average of kr204.65.

more news about totens sparebank.

3. axa (cs.pa)

50.66% payout ratio

axa sa, through its subsidiaries, provides insurance, asset management, and banking services worldwide. the company operates through six segments: france, europe, asia, axa xl, international, and transversal & central holdings. it offers life and savings insurance products, such as savings and retirement, other health, and personal protection products. the company also provides property and casualty insurance products, including car, home, and personal or professional liability to individual and business clients; international insurance for large corporate clients in europe; and marine and aviation insurance services, as well as property and casualty reinsurance products. in addition, it offers asset management services in the areas of various asset classes, including equities, bonds, hedge funds, private equity, and real estate for the group's insurance companies and their clients, and retail and institutional clients. further, the company provides health, term life, whole life, universal life, endowment, and other investment-based products for personal/individual and commercial/ group customers. axa sa was founded in 1852 and is headquartered in paris, france.

earnings per share

as for profitability, axa has a trailing twelve months eps of €2.83.

pe ratio

axa has a trailing twelve months price to earnings ratio of 9.56. meaning, the purchaser of the share is investing €9.56 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.69%.

yearly top and bottom value

axa's stock is valued at €27.07 at 22:10 est, below its 52-week high of €28.95 and way higher than its 52-week low of €20.33.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 6, 2022, the estimated forward annual dividend rate is 1.54 and the estimated forward annual dividend yield is 5.44%.

volume

today's last reported volume for axa is 1036490 which is 80.59% below its average volume of 5340480.

more news about axa.

4. dsm kon (dsm.as)

40% payout ratio

dsm-firmenich ag, a science-based company, engages in health and nutrition businesses in the netherlands, switzerland, rest of europe, north america, latin america, china, rest of asia, and internationally. it operates through animal nutrition & health (anh); health, nutrition & care (hnc); and food & beverage segments. the animal nutrition & health segment offers essential products, including vitamins, premixes, and carotenoids; performance solutions, such as enzymes, microbes, and eubiotics; precision services comprising support with data analysis to measure animal health and environmental footprint on farm level and feed safety; and methane reducing feed additive for ruminants. the health, nutrition & care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, personal care and aroma, and biomedical materials markets. it offers vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics and prebiotics, active pharmaceutical ingredients, and sunscreen filters, as well as a range of biomedical solutions; premix, market-ready solutions, and personalized nutrition solutions; and regulatory affairs and formulation expertise, and customized solutions. the food & beverage segment provides ingredients and solutions for use in a range of food products, such as dairy; bakery, cereals, and bars; savory foods; beverages and brewing; confectionery and fruit; plant-based meat and fish alternatives; and petfood. the company was founded in 1902 and is headquartered in heerlen, the netherlands.

earnings per share

as for profitability, dsm kon has a trailing twelve months eps of €6.25.

pe ratio

dsm kon has a trailing twelve months price to earnings ratio of 18.1. meaning, the purchaser of the share is investing €18.1 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.69%.

revenue growth

year-on-year quarterly revenue growth declined by 9.4%, now sitting on 8.39b for the twelve trailing months.

moving average

dsm kon's worth is below its 50-day moving average of €113.98 and under its 200-day moving average of €120.50.

yearly top and bottom value

dsm kon's stock is valued at €113.10 at 22:10 est, way under its 52-week high of €164.00 and higher than its 52-week low of €105.80.

volume

today's last reported volume for dsm kon is 15924 which is 95.83% below its average volume of 382690.

more news about dsm kon.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com